MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Viking Therapeutics Inc

Open

SectorGezondheidszorg

24.57 -4.51

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.3

Max

25.87

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

-35M

EPS

-0.32

Werknemers

36

EBITDA

-9.6M

-46M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+248.66% upside

Dividenden

By Dow Jones

Volgende Winsten

23 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-570M

2.7B

Vorige openingsprijs

29.08

Vorige sluitingsprijs

24.57

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Viking Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 apr 2025, 14:14 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

7 feb 2025, 10:30 UTC

Top Nieuws

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 dec 2024, 15:04 UTC

Top Nieuws

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dec 2024, 14:53 UTC

Top Nieuws

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 nov 2024, 12:22 UTC

Top Nieuws

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 nov 2024, 12:00 UTC

Top Nieuws

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 nov 2024, 10:11 UTC

Populaire aandelen

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 okt 2024, 12:01 UTC

Top Nieuws

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 okt 2024, 12:01 UTC

Top Nieuws

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 sep 2024, 13:55 UTC

Top Nieuws

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 jul 2024, 15:03 UTC

Winsten

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Peer Vergelijking

Prijswijziging

Viking Therapeutics Inc Prognose

Koersdoel

By TipRanks

248.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 89.92 USD  248.66%

Hoogste 125 USD

Laagste 30 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Viking Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

15

Buy

2

Hold

0

Sell

Technische score

By Trading Central

25.48 / 25.7Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.